AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$VERA

Fordyce Marshall sold $2.0M of VERA

Fordyce Marshall (PRESIDENT AND CEO) sold 46,250 shares of Vera Therapeutics, Inc. (VERA) at an average of $42.30 ($40.78–$43.59, $1.96M total) across 4 trades on 2026-07-07 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Fordyce Marshall
Published Jul 9, 2026, 8:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 9, 2026, 8:48 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$VERA
Neutral
medium confidence
Mentioned
$VERA
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$VERANeutralLow
01

Why it matters

Because the transaction is an open-market sale under a pre-arranged 10b5-1 plan, it is more relevant for sentiment monitoring than for forecasting fundamentals.

02

Market read

Traders may watch for follow-on insider activity, but there is no new company-specific operating or financial datapoint here.

03

What to watch

The article provides no context on motivations, tax planning, or whether other insiders also sold/bought around the same time.

Relevance 5/10Novelty 3/10Timing: Filed July 9, covering sales executed July 7.

Background

The article is an SEC Form 4 insider transaction by Vera Therapeutics CEO Fordyce Marshall.

Company-level read

Ticker impact

$VERANeutralMedium confidence
Context

Vera Therapeutics CEO Fordyce Marshall sold about $1.96M of VERA shares via an open-market sale under a 10b5-1 plan.

Expected impact

Likely limited, with any effect more sentiment-driven than fundamental.

Evidence & confidence

The filing is a Form 4 insider transaction with a stated 10b5-1 pre-arranged plan; insider sales are common and typically have muted causal impact versus earnings, guidance, or trial/regulatory news.

Market effects

Sector

Minimal; insider-sale disclosures rarely reset sector expectations without accompanying operational news.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

The sale could be purely planned liquidity (10b5-1) and may not signal reduced confidence.

Key entities

  • issuer
    Vera Therapeutics, Inc.

    Company whose CEO filed the Form 4 insider sale disclosure.

  • insider
    Fordyce Marshall

    President and CEO who sold 46,250 shares across four trades on July 7, 2026.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

VERA insider trading history →

Related articles

$VERAMed

Vera Therapeutics Inc (VERA) (Q3 2026) Earnings Call Highlights: TRUTAKNA Launch Off

Vera Therapeutics (VERA) reported $10.3M in Q3 TRUTAKNA revenue, split evenly between inventory and demand. The company expects demand to rise. Chief Medical Officer Robert Brenner discussed potential label changes post-ORIGIN 3 data, and Chief Commercial Officer Matt Skelton provided updates on prescription trends and market access. Vera aims for 50% covered lives by year-end. The company is also conducting a dose-range study for atacicept, with data expected later this quarter.

finance.yahoo.com
$VERAMedAI 8/10

Vera Therapeutics Q3 Earnings Call Highlights

Vera Therapeutics (VERA) reported Q3 net loss of $93.7M, up from $80.3M YoY, due to launch spending. TRUTAKNA showed positive kidney disease progression results, with 76% risk reduction vs. placebo. Vera has $459M in cash and expects U.S. approval in mid-2027. Additional studies on atacicept are ongoing.

finance.yahoo.com
$VERAMedAI 8/10

Vera Therapeutics (VERA) Q3 2026 Earnings Call Transcript

Vera Therapeutics (VERA) reported strong early demand for TRUTAKNA, its newly FDA-approved therapy for IgA nephropathy, with 700 patient start forms since July. The company submitted a supplemental biologics licensing application for full FDA approval, citing final efficacy results from the ORIGIN 3 trial, which showed a 76% reduction in kidney disease progression risk. Vera also plans to submit a marketing authorization application in Europe in Q1 2027.

finance.yahoo.com
$VERAMed

Vera Therapeutics Provides Business Update and Reports Third Quarter 2026 Financial Results

Vera Therapeutics, Inc. (VERA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Vera Therapeutics Provides Business Update and Reports Third Quarter 2026 Financial Results • TRUTAKNA® (atacicept-vymj) U.S. launch building early momentum following July 7 accelerated approval by the U.S. Food and Drug Administration (FDA) with approximately 700 Pa

SEC EDGAR 8-K